Monkeypox Treatment Market: Focus on Therapeutics, Vaccines and Diagnostic Kits: Distribution by Type of Product (Therapeutics and Vaccines), Drug Developers, Drug Candidates, Type of Diagnostic Kit (PCR Kits, Antigen Detection Kits and Antibody Detection Kits), Type of End User (Hospitals and Clinics, Diagnostic Laboratories and Other End Users) and Key Geographical Regions (North America (US, Canada), Europe (UK, Germany, Spain, France, Italy, Rest Of Europe) and Asia-Pacific (Japan, Australia)): Industry Trends and Global Forecasts, 2023-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    January 2023

  • Slides
    138

  • View Count
    263

Example Insights

Monkeypox-Market-Context-thumb Monkeypox-Market-Therapeutics-and-Vaccines-thumb Monkeypox-Market-oral-administration-thumb Monkeypox-Market-Diagnostic-Kits-thumb
Monkeypox-Market-Detection-Method-thumb Monkeypox-Market-Competitiveness-Analysis-thumb Monkeypox-Market-Collaborations-thumb Monkeypox-Market-Grant-Analysis-thumb
Monkeypox-Market-Publication-Analysis-thumb Monkeypox-Market-Forces-Analysis-thumb Monkeypox-Market-foreseen-future-thumb Monkeypox-Market-geographical-regions-thumb

Overview

Monkeypox is a viral disease, which is usually transmitted to humans from animals. The disease is known to have symptoms similar to those observed in smallpox patients, although it is considered to be clinically less severe. Monkeypox has recently emerged as a prominent orthopox virus affecting public health. In May 2022, multiple cases of the disease were reported in several non-endemic countries, thereby making monkeypox a disease of global concern. Consequently, in July 2022, the World Health Organization (WHO) declared global monkeypox outbreak a Public Health Emergency of International Concern (PHEIC). In fact, till date, over 71,000 cases of the disease have been reported, globally. In response to the monkeypox outbreak, active research and development efforts are underway to develop various therapeutics and vaccines for the treatment and prevention of monkeypox. Presently, more than 25 therapeutics / vaccines are commercialized / under development for the treatment and prevention of monkeypox. With the increase in the number of monkeypox cases globally, the demand for testing has also increased.

Key Market Insights

The Monkeypox Treatment Market - Distribution by Type of Product (Therapeutics and Vaccines), Drug Developers, Drug Candidates, Type of Diagnostic Kit (PCR Kits, Antigen Detection Kits and Antibody Detection Kits), Type of End User (Hospitals and Clinics, Diagnostic Laboratories and Other End Users) and Key Geographical Regions ( North America (US, Canada), Europe (UK, Germany, Spain, France, Italy, Rest Of Europe) and Asia-Pacific (Japan, Australia)): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape and future opportunity for the players focused on the development of monkeypox therapeutics, vaccines and diagnostic kits. The report answers many key questions related to this domain.

Growing Demand for Monkeypox Treatment Therapeutics / Vaccines and Diagnostic Kits

Due to the surge in monkeypox cases in 2022, globally, there is a growing demand for monkeypox vaccines, therapeutics and diagnostic kits. With only a few therapeutics / vaccines currently approved or granted special access for the treatment / prevention of the monkeypox disease, the existing demand for effective monkeypox vaccines and therapeutics is still unmet. Additionally, the approved monkeypox vaccines are available at a high price, making it inaccessible to general population in developing countries, where the disease is endemic. In order to contain an outbreak, point-of-care diagnostics is very critical to ensure timely isolation and enable contact tracing of infected individuals. Therefore, considering the demand for diagnostic solutions for monkeypox virus, and the associated financial opportunity, both large companies and start-ups are competing to gain a foothold in this market.

Current Market Landscape of Monkeypox Treatment Therapeutics and Vaccines

The current monkeypox therapeutics and vaccines landscape is fragmented, featuring a mix of several large, mid-sized and small companies, which are engaged in the development of a number of therapy and vaccine candidates against the monkeypox virus. It is worth mentioning that, till date, only six therapeutics / vaccines, including ACAM2000®, IMVANEX® / JYNNEOS® / IMVAMUNE® and Cidofovir / Vistide, have either received approval or been granted special access for the treatment / prevention of the monkeypox virus infection. Additionally, more than 20 monkeypox therapeutics and vaccines are in the development pipeline. Post the 2022 outbreak of the monkeypox disease globally, interest in this area of research has grown significantly.

Current Market Overview of Monkeypox Diagnostic Kits

At present, more than 165 diagnostic kits are available in the market for the detection of monkeypox virus. It is worth highlighting that over 75% of the monkeypox diagnostic kits use polymerase chain reaction (PCR) as the detection technique, followed by antigen detection kits and antibody detection kits. In pursuit of gaining a competitive edge, monkeypox diagnostic kit providers are presently undertaking various initiatives in order to expand their existing capabilities and augment their respective product portfolios.

Key Drivers in Monkeypox Therapeutics / Vaccines and Diagnostic Kits Market

More than 70 countries across the world reported cases of monkeypox, with the maximum cases being reported in non-endemic regions. This outbreak has posed the risk of monkeypox virus spreading beyond endemic areas. Consequently, governments have undertaken several initiatives to increase awareness about monkeypox disease. Big pharma players are carrying out initiatives to strengthen their respective product portfolios focused on monkeypox disease. The growing cases of monkeypox disease and availability of limited number of therapeutics / vaccines / diagnostic solutions are the key factors driving the growth of this market. 

Market Size of Monkeypox Treatment Therapeutics and Vaccines 

Due to the increase in incidence of monkeypox infections and the growing demand for monkeypox vaccines and therapeutics, the monkeypox market is anticipated to witness a steady growth in the foreseen future. Presently, close to 80% of the monkeypox therapeutics and vaccines market is captured by players based in North America and Asia-Pacific.

Market Size of Monkeypox Diagnostic Kits

The market for monkeypox diagnostic kits is anticipated to increase steadily in the foreseeable future due to the growing cases of the disease and the possibility of future outbreaks. Currently, over 60% of the diagnostic kits market is captured by players based in Asia-Pacific.

Key Players in Monkeypox Therapeutics, Vaccines and Diagnostic Kits Market

Examples of key players engaged in the monkeypox therapeutics and vaccines domain include (which have also been captured in this report) Bavarian Nordic and Emergent BioSolutions. Further, key players engaged in the monkeypox diagnostic kits domain include (which have also been captured in this report) ACON Laboratories, altona Diagnostics, Jiangsu Bioperfectus Technologies, Elabscience, Goldsite Diagnostics, Lansion Biotechnology, DNA Software and Hangzhou Testsea Biotechnology.

Scope of the Report

The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different segments as defined in the below table:
 

Report Attribute Details

Forecast Period

2023 – 2035

Type of Product

Therapeutics, Vaccines

Drug Developers

Company 1, Company 2, Company 3, Company 4 and Company 5

Drug Candidates

Drug Candidate 1, Drug Candidate 2, Drug Candidate 3, Drug Candidate 4, Drug Candidate 5, Drug Candidate 6 and Drug Candidate 7

Types of Kits

PCR Kits, Antigen Detection Kits and Antibody Detection Kits

Type of End Users

Hospitals and Clinics, Diagnotic Laboratories and Other End Users
Key Geographical Regions North America (US and Canada), Europe (UK, France, Germany, Spain, Italy, Rest of EU) and Asia-Pacific (Japan and Australia)
Key Companies Profiled Software, Elabscience, Goldsite Diagnostics, Hangzhou Testsea Biotechnology, Jiangsu Bioperfectus Technologies, Lansion Biotechnology, Bavarian Nordic and Emergent BioSolutions
Customization Scope 15% Free Customization Option (equivalent to 5 analyst working days)
PowerPoint Presentation (Complimentary) Available
Excel Data Packs (Complimentary) Market Landscape Analysis, Product Competitiveness Analysis, Partnership and Collaboration Analysis, Grant Analysis, Publication Analysis, Porter's Five Forces Analysis, Market Forecast an Opportunity Analysis


Amongst other elements, the report also includes:

  • An executive summary of the insights captured during our research. It offers a high-level view on the current state of the monkeypox market and its likely evolution in the mid-long term.
  • A general introduction to monkeypox virus, along with information on signs and symptoms of the disease, history of monkeypox outbreaks and details on transmission of disease from animals to humans and humans to humans. It also features an overview of the monkeypox disease diagnosis and current therapeutics / vaccines used for the treatment / prevention of the infection and a discussion on future prospects of this domain.
  • A detailed assessment of the current market landscape of monkeypox therapeutics / vaccines that are approved / under development, based on several relevant parameters, such as phase of development (approved, clinical and preclinical / discovery), type of product (therapeutic drugs and vaccines), type of molecule (small molecules and biologics), type of dosage form (tablets, capsules, liquids, powders and others), route of administration (oral, intravenous, percutaneous and subcutaneous). In addition, it provides details on monkeypox drug / vaccine developers, along with analyses based on their year of establishment, type of player (Industry and Non-Industry), company size (Small companies: ≤50 employees, Mid-sized companies: 51-500 employees and Large companies: >500 employees), geographical location (North America, Europe, Asia Pacific and Rest of the World) and leading players (in terms of number of therapeutics / vaccines in pipeline).
  • A detailed assessment of the current market landscape of monkeypox diagnostic kits, based on several relevant parameters, such as type of sample analyzed (lesion swab / rash exudate, serum, blood, respiratory samples, plasma, scab specimen and others), kit components (primer, probe, positive control, negative control, internal control, buffer, enzyme mix, reaction mix, PCR grade water and others), clade of virus detected (monkeypox virus – clade unspecified, West African clade, Congo Basin clade and orthopox virus – including monkeypox), detection method (Polymerase Chain Reaction and others), application area (clinical diagnostics and research), type of kit (DNA detection kit, antibody detection kit, antigen detection kit), quantity of sample required (2-10 µL, 11-50 µL, 51-100 µL and > 100 µL), turnaround time (5-30 minutes, 31-60 minutes, 61-90 minutes and > 90 minutes), limit of detection (100-200 copies/ mL, 201-500 copies/ mL, 501-1,000 copies/ mL and > 1,000 copies/ mL), number of tests per kit (15-50 tests/ kit, 51-150 tests/ kit, 151-500 tests/ kit and > 500 tests/ kit), shelf life (1-9 months, 9-12 months and 12-24 months) and storage temperature (ultra-low storage (-70°C to -40°C), frozen storage (-40°C to 0°C), chilled storage (2°C to 8°C), cool storage (8°C to 15°C), controlled ambient storage (15°C to 25°C) and incubator storage (25°C to 60°C)). In addition, it provides details on monkeypox diagnostic kits developers, along with analyses based on their year of establishment, company size (Small companies: ≤50 employees, Mid-sized companies: 51-500 employees, Large Companies: 501 - 1,000 and Very Large companies: >1,000 employees), geographical location (North America, Europe, Asia Pacific and Rest of the World), type of developer (Industry and Non-Industry), and leading players (in terms of number of kits provided).
  • A product competitiveness analysis of monkeypox detection kits based on various relevant parameters, namely supplier power (in terms of the experience of the developer) and product competitiveness (in terms of type of clade of virus detected, number of kit component(s), number of sample(s) used, turnaround time, number of tests per kit, storage temperature, kit shelf life, type of detection method, and type of kit).
  • Elaborate profiles of prominent players engaged in the development of monkeypox therapeutics / vaccines and diagnostic kits, featuring a brief overview of the company, details on its product portfolio and recent developments with an informed future outlook.
  • A detailed analysis of the recent partnerships inked between stakeholders engaged in this domain, during the period 2018-2022, covering supply agreements, product development agreements, asset acquisitions, distribution agreements, fill / finish agreements, research and development agreements, and technology integration agreements. 
  • An in-depth analysis on various grants, received since the year 2003, by players engaged in this field based on year of award, support period, amount awarded, funding institute, type of grant application, activity code, type of study section, purpose of grant, prominent program officers, recipient organizations, popular NIH departments and location of recipient organizations.
  • A detailed analysis of more than 200 peer-reviewed, scientific articles related to research on monkeypox therapeutics / vaccines and diagnostic kits, over last five years, based on several relevant parameters, such as year of publication, type of publication, most popular journals, popular keywords, most active publishers, most popular affiliations, and distribution by geography.
  • A qualitative analysis of the five competitive forces, including threats for new entrants, bargaining power of drug developers, bargaining power of buyers, threats of substitute products and rivalry among existing competitors under an insightful Porter's Five Forces framework.

One of the key objectives of this report was to estimate the existing market opportunity and the future growth potential of the monkeypox therapeutics / vaccines and diagnostic kits over the coming years. Based on multiple parameters, such as incidences of monkeypox, target population to be vaccinated / treated, cost of therapeutics / vaccines, we have provided an informed estimate on the evolution of the monkeypox therapeutics / vaccines market for the period 2023-2035. Similarly, we have estimated the monkeypox diagnostic kits market for the period 2023-2035 based on multiple parameters, such as incidences of monkeypox, testing population across the world, popularity of type of kits available and cost of kits. The report features the likely distribution of the current and forecasted opportunity across various types of products (therapeutics and vaccines), drug developers, drug candidates and key geographical regions (North America (US, Canada), Europe (UK, Germany, Spain, France, Italy, Rest of Europe) and Asia-Pacific (Japan, Australia)) for monkeypox therapeutics / vaccines market. For monkeypox diagnostic kits market, the report features likely distribution of the current and forecasted opportunity across various types of kits (PCR Kits, Antigen Detection Kits and Antibody Detection Kits), type of end users (Hospitals and Clinics, Diagnostic Laboratories and Other End Users) and key geographical regions (North America (US, Canada), Europe (UK, Germany, Spain, France, Italy, Rest of Europe) and Asia-Pacific (Japan, Australia))

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals:

  • Willy Tozoke Laou Man Cheong (Business Director, Hunan Runmei Gene Technology)
  • John W Sharkey (Vice President, Business Development, GeoVax)
  • Horace Lee (Sales Manager, Firegene) 
  • Alan Yu (Sales Manager, Hangzhou Testsea Biotechnology)

Frequently Asked Questions

Question 1: What are the first signs of monkeypox?
Answer: The first signs and symptoms of monkeypox include high temperature, headache, muscle ache, backache, swollen glands, chills, joint pain and exhaustion. 

Question 2: What is the growth rate of monkeypox therapeutics and vaccines market?
Answer: Monkeypox therapeutics / vaccines market is anticipated to witness a decline over the next decade; this is likely to be the result of a dip in the number of monkeypox cases till 2035.

Question 3: What is the growth rate of monkeypox diagnostic kits market?
Answer: Monkeypox diagnostic kits market is expected to witness a decline over the next decade due to the dip in the number of monkeypox cases till 2035.

Question 4: Who are the key developers of monkeypox therapeutics / vaccines?
Answer: Examples of key players currently developing monkeypox therapeutics / vaccines include Bavarian Nordic, Emergent BioSolutions and KM Biologics and SIGA Technologies.

Question 5: Who are the key developers of monkeypox diagnostic kits? 
Answer: Examples of key players currently developing monkeypox diagnostic kits include ACON Laboratories, altona Diagnostics, DNA Software, Elabscience, Goldsite Diagnostics, Hangzhou Testsea Biotechnology, Jiangsu Bioperfectus Technologies and Lansion Biotechnology.

Question 6: How many players are offering monkeypox therapeutics / vaccines and diagnostic kits?
Answer: Currently, more than 20 players are developing monkeypox therapeutics / vaccines. Additionally, over 120 players are involved in the development of diagnostic kits for monkeypox. 

Question 7: What is the count of monkeypox diagnostic kits available in the market?
Answer: At present, more than 150 monkeypox diagnostic kits are available in the market. Moreover, close to 10 kits are currently under development for diagnosis of monkeypox.

Question 8: How many therapeutics and vaccines are approved for the treatment and prevention of monkeypox?
Answer: Presently, six therapeutics / vaccines have been approved or granted special access for the treatment / prevention of monkeypox.

Question 9: Which type of diagnostic kit accounts for the largest monkeypox market share?
Answer: In the current market, polymerase chain reaction (PCR) based detection kits for monkeypox represent the largest market share.

Question 10: Which segment, in terms of type of product, accounts for the largest monkeypox therapeutics / vaccines market share?
Answer: At present, vaccines account for the largest market share, in terms of revenues, in the global monkeypox therapeutics / vaccines market.

Contents

Table Of Contents

1. EXECUTIVE SUMMARY

2. INTRODUCTION
2.1. An Overview of Monkeypox
2.2. Signs and Symptoms
2.3. History of Disease Outbreaks
2.4. Disease Transmission
2.5. Disease Diagnosis
2.6. Prevention and Treatment
2.6.1. Prevention Measures
2.6.2. Available Therapeutics and Vaccines
2.7. Future Perspectives

3. MARKET LANDSCAPE: MONKEYPOX TARGETING THERAPEUTICS AND VACCINES
3.1. Monkeypox Targeting Therapeutics and Vaccines: Overall Market Landscape
3.1.1. Analysis by Phase of Development
3.1.2. Analysis by Type of Product
3.1.3. Analysis by Phase of Development and Type of Product
3.1.4. Analysis by Type of Molecule
3.1.5. Analysis by Type of Dosage Form
3.1.6. Analysis by Route of Administration

3.2. Monkeypox Targeting Therapeutics and Vaccines: Developer Landscape
3.2.1. Analysis by Year of Establishment
3.2.2. Analysis by Type of Player
3.2.3. Analysis by Geography (Region-wise)
3.2.4. Analysis by Company Size and Geography (Region-wise)
3.2.5. Leading Developers: Analysis by Number of Therapeutics / Vaccines

4. MARKET LANDSCAPE: MONKEYPOX DIAGNOSTIC KITS
4.1. Monkeypox Diagnostic Kits: Overall Market Landscape
4.1.1. Analysis by Type of Sample
4.1.2. Analysis by Type of Kit Component
4.1.3. Analysis by Clade of Virus Detected
4.1.4. Analysis by Detection Method
4.1.5. Analysis by Application Area
4.1.6. Analysis by Type of Kit
4.1.7. Analysis by Quantity of Sample
4.1.8. Analysis by Turnaround Time
4.1.9 Analysis by Limit of Detection
4.1.10. Analysis by Number of Tests per Kit
4.1.11. Analysis by Shelf Life
4.1.12. Analysis by Storage Temperature

4.2 Monkeypox Diagnostic Kits: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Type of Developer
4.2.6. Key Developers: Analysis by Number of Diagnostic Kits Developed

5. MONKEYPOX DIAGNOSTIC KITS: PRODUCT COMPETITIVENESS ANALYSIS
5.1. Methodology
5.2. Product Competitiveness Analysis: Monkeypox Diagnostic Kits

6. COMPANY PROFILES: MONKEYPOX TARGETING THERAPEUTICS AND VACCINES DEVELOPERS
6.1. Bavarian Nordic
6.1.1. Company Overview
6.1.2. Monkeypox Therapeutics / Vaccines Portfolio
6.1.3. Recent Developments and Future Outlook

6.2. Emergent BioSolutions
6.2.1. Company Overview
6.2.2. Monkeypox Therapeutics / Vaccines Portfolio
6.2.3. Recent Developments and Future Outlook

7. COMPANY PROFILES: MONKEYPOX DIAGNOSTIC KITS DEVELOPERS
7.1. ACON Laboratories
7.1.1. Company Overview
7.1.2. Monkeypox Diagnostic Kits Portfolio

7.2. altona Diagnostics
7.2.1. Company Overview
7.2.2. Monkeypox Diagnostic Kits Portfolio
7.2.3. Recent Developments and Future Outlook

7.3. DNA Software
7.3.1. Company Overview
7.3.2. Monkeypox Diagnostic Kits Portfolio

7.4. Elabscience
7.4.1. Company Overview
7.4.2. Monkeypox Diagnostic Kits Portfolio

7.5. Goldsite Diagnostics
7.5.1. Company Overview
7.5.2. Monkeypox Diagnostic Kits Portfolio

7.6. Hangzhou Testsea Biotechnology
7.6.1. Company Overview
7.6.2. Monkeypox Diagnostic Kits Portfolio
7.6.3. Recent Developments and Future Outlook

7.7. Jiangsu Bioperfectus Technologies
7.7.1. Company Overview
7.7.2. Monkeypox Diagnostic Kits Portfolio
7.7.3. Recent Developments and Future Outlook

7.8. Lansion Biotechnology
7.8.1. Company Overview
7.8.2. Monkeypox Diagnostic Kits Portfolio

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Monkeypox Targeting Therapeutics / Vaccines and Diagnostic Kits: Partnerships and Collaborations
8.1.1. Analysis by Year of Partnership
8.1.2. Analysis by Type of Partnership
8.1.3. Analysis by Year and Type of Partnership
8.1.4. Analysis by Focus Area
8.1.5. Analysis by Type of Partner
8.1.6. Most Active Players: Analysis by Number of Partnerships
8.1.7. Analysis by Local and International Agreements
8.1.8. Analysis by Intercontinental and Intracontinental Agreements

9. GRANTS ANALYSIS
9.1. Scope and Methodology
9.2. Key Parameters
9.3. Monkeypox Targeting Therapeutics / Vaccines and Diagnostic Kits: Grants Analysis
9.3.1. Analysis by Year of Grant Awarded
9.3.2. Analysis by Support Period
9.3.3. Analysis by Amount Awarded
9.3.4. Analysis by Leading Funding Institute Centre
9.3.5. Analysis by Type of Grant
9.3.6. Analysis by Activity Code
9.3.7. Analysis by Study Section Involved
9.3.8. Analysis by Purpose of Grant
9.3.9. Prominent Program Officers: Analysis by Number of Grants
9.3.10. Popular Recipient Organizations: Analysis by Number of Grants and Amount Awarded
9.3.11. Most Popular Departments: Analysis by Number of Grants
9.3.12. Analysis by Location of Recipient

10. PUBLICATION ANALYSIS
10.1. Methodology and Parameters
10.2. Monkeypox Targeting Therapeutics / Vaccines and Diagnostic Kits: Publication Analysis
10.2.1. Analysis by Year of Publication
10.2.2. Analysis by Type of Publication
10.2.3. Most Popular Journals: Analysis by Number of Publications
10.2.4. Most Popular Journals: Analysis by Journal Impact Factor
10.2.5. Popular Keywords: Analysis by Key Focus Areas
10.2.6. Most Active Publishers: Analysis by Number of Publications
10.2.7. Most Popular Affiliations: Analysis by Number of Publications
10.2.8. Analysis by Geography

11. PORTER’S FIVE FORCES ANALYSIS
11.1. Chapter Overview
11.2. Methodology and Key Parameters
11.3. Porter’s Five Forces
11.3.1. Threat of New Entrants
11.3.2. Bargaining Power of End Users
11.3.3. Bargaining Power of Drug Developers
11.3.4. Threat of Substitute Products
11.3.5. Rivalry Among Existing Competitors

12. MARKET FORECAST: MONKEYPOX TARGETING THERAPEUTICS AND VACCINES
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
12.3. Global Monkeypox Targeting Therapeutics and Vaccines Market, 2023-2035
12.3.1. Monkeypox Targeting Therapeutics and Vaccines Market: Analysis by Type of Product, 2023 and 2035
12.3.1.1. Monkeypox Targeting Therapeutics Market, 2023-2035
12.3.1.2. Monkeypox Targeting Vaccines Market, 2023-2035

12.3.2. Monkeypox Targeting Therapeutics and Vaccines Market: Analysis by Drug Developers, 2023 and 2035
12.3.2.1. Monkeypox Targeting Therapeutics and Vaccines Market for Bavarian Nordic, 2023-2035
12.3.2.2. Monkeypox Targeting Therapeutics and Vaccines Market for SIGA Technologies, 2023-2035
12.3.2.3. Monkeypox Targeting Therapeutics and Vaccines Market for Emergent BioSolutions, 2023-2035
12.3.2.4. Monkeypox Targeting Therapeutics and Vaccines Market for Gilead Sciences, 2023-2035
12.3.2.5. Monkeypox Targeting Therapeutics and Vaccines Market for KM Biologics, 2023-2035

12.3.3. Monkeypox Targeting Therapeutics and Vaccines Market: Analysis by Drug Candidates, 2023 and 2035
12.3.3.1. IMVANEX® / JYNNEOS® / IMVAMUNER® (Bavarian Nordic): Sales Forecast, 2023-2035
12.3.3.2. Tecovirimat / ST-246 / TPOXX (SIGA Technologies): Sales Forecast, 2023-2035
12.3.3.3. ACAM2000 (Emergent BioSolutions): Sales Forecast, 2023-2035
12.3.3.4. VIGIV / CNJ-016 (Emergent BioSolutions): Sales Forecast, 2023-2035
12.3.3.5. Brincidofovir / CMX001 / Tembexa (Emergent BioSolutions / SymBio Pharmaceuticals): Sales Forecast, 2023-2035
12.3.3.6. Cidofovir / Vistide (Gilead Sciences): Sales Forecast, 2023-2035
12.3.3.7. LC16KMB (KM Biologics): Sales Forecast, 2023-2035

12.3.4. Monkeypox Targeting Therapeutics and Vaccines Market: Analysis by Geography, 2023 and 2035
12.3.4.1. Monkeypox Targeting Therapeutics and Vaccines Market in North America, 2023-2035
12.3.4.1.1. Monkeypox Targeting Therapeutics and Vaccines Market in the US, 2023-2035
12.3.4.1.2. Monkeypox Targeting Therapeutics and Vaccines Market in Canada, 2023-2035

12.3.4.2. Monkeypox Targeting Therapeutics and Vaccines Market in Europe, 2023-2035
12.3.4.2.1. Monkeypox Targeting Therapeutics and Vaccines Market in the UK, 2023-2035
12.3.4.2.2. Monkeypox Targeting Therapeutics and Vaccines Market in France, 2023-2035
12.3.4.2.3. Monkeypox Targeting Therapeutics and Vaccines Market in Germany, 2023-2035
12.3.4.2.4. Monkeypox Targeting Therapeutics and Vaccines Market in Spain, 2023-2035
12.3.4.2.5. Monkeypox Targeting Therapeutics and Vaccines Market in Italy, 2023-2035
13.3.4.2.6. Monkeypox Targeting Therapeutics and Vaccines Market in Rest of Europe, 2023-2035

12.3.4.3. Monkeypox Targeting Therapeutics and Vaccines Market in Asia Pacific, 2023-2035
12.3.4.3.1. Monkeypox Targeting Therapeutics and Vaccines Market in Japan, 2023-2035
12.3.4.3.2. Monkeypox Targeting Therapeutics and Vaccines Market in Australia, 2023-2035

13. MARKET FORECAST: MONKEYPOX DIAGNOSTIC KITS
13.1. Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global Monkeypox Diagnostic Kits Market, 2023-2035
13.3.1. Monkeypox Diagnostic Kits Market: Analysis by Type of Kit, 2023 and 2035
13.3.1.1. Monkeypox Polymerase Chain Reaction (PCR) Detection Kits Market, 2023-2035
13.3.1.2. Monkeypox Antigen Detection Kits Market, 2023-2035
13.3.1.3 Monkeypox Antibody Detection Kits Market, 2023-2035

13.3.2. Monkeypox Diagnostic Kits Market: Analysis by Type of End User, 2023 and 2035
13.3.2.1. Monkeypox Diagnostic Kits Market for Hospitals and Clinics, 2023-2035
13.3.2.2. Monkeypox Diagnostic Kits Market for Diagnostic Laboratories, 2023-2035
13.3.2.3. Monkeypox Diagnostic Kits Market for Other End Users, 2023-2035

13.3.3. Monkeypox Diagnostic Kits Market: Analysis by Geography, 2023 and 2035
13.3.3.1. Monkeypox Diagnostic Kits Market in North America, 2023-2035
13.3.3.1.1. Monkeypox Diagnostic Kits Market in the US, 2023-2035
13.3.3.1.2. Monkeypox Diagnostic Kits Market in Canada, 2023-2035

13.3.3.2. Monkeypox Diagnostic Kits Market in Europe, 2023-2035
13.3.3.2.1. Monkeypox Diagnostic Kits Market in the UK, 2023-2035
13.3.3.2.2. Monkeypox Diagnostic Kits in France, 2023-2035
13.3.3.2.3. Monkeypox Diagnostic Kits Market in Germany, 2023-2035
13.3.3.2.4. Monkeypox Diagnostic Kits Market in Spain, 2023-2035
13.3.3.2.5. Monkeypox Diagnostic Kits Market in Italy, 2023-2035
13.3.3.2.6. Monkeypox Diagnostic Kits Market in Rest of Europe, 2023-2035

13.3.3.3. Monkeypox Diagnostic Kits Market in Asia Pacific, 2023-2035
13.3.3.3.1. Monkeypox Diagnostic Kits Market in Japan, 2023-2035
13.3.3.3.2. Monkeypox Diagnostic Kits Market in Australia, 2023-2035

14. EXECUTIVE INSIGHTS

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 1.1 Executive Summary: Overall Market Landscape of Monkeypox Therapeutics and Vaccines
Figure 1.2 Executive Summary: Overall Market Landscape of Monkeypox Diagnostic Kits
Figure 1.3 Executive Summary: Partnerships and Collaborations
Figure 1.4 Executive Summary: Grant Analysis
Figure 1.5 Executive Summary: Publication Analysis
Figure 1.6 Executive Summary: Market Forecast and Opportunity Analysis of Monkeypox Therapeutics and Vaccines
Figure 1.7 Executive Summary: Market Forecast and Opportunity Analysis of Monkeypox Diagnostic Kits
Figure 3.1 Monkeypox Therapeutics / Vaccines: Distribution by Phase of Development
Figure 3.2 Monkeypox Therapeutics / Vaccines: Distribution by Type of Product
Figure 3.3 Monkeypox Therapeutics / Vaccines: Distribution by Phase of Development and Type of Product
Figure 3.4 Monkeypox Therapeutics / Vaccines: Distribution by Type of Molecule
Figure 3.5 Monkeypox Therapeutics / Vaccines: Distribution by Type of Dosage Form
Figure 3.6 Monkeypox Therapeutics / Vaccines: Distribution by Route of Administration
Figure 3.7 Monkeypox Therapeutics / Vaccines Developers: Distribution by Year of Establishment
Figure 3.8 Monkeypox Therapeutics / Vaccines Developers: Distribution by Type of Player
Figure 3.9 Monkeypox Therapeutics / Vaccines Developers: Distribution by Geography (Region-wise)
Figure 3.10 Monkeypox Therapeutics / Vaccines Developers: Distribution by Company Size and Geography (Region-wise)
Figure 3.11 Leading Developers: Distribution by Number of Therapeutics / Vaccines
Figure 4.1 Monkeypox Diagnostic Kits: Distribution by Type of Sample
Figure 4.2 Monkeypox Diagnostic Kits: Distribution by Type of Kit Component
Figure 4.3 Monkeypox Diagnostic Kits: Distribution by Clade of Virus Detected
Figure 4.4 Monkeypox Diagnostic Kits: Distribution by Detection Method
Figure 4.5 Monkeypox Diagnostic Kits: Distribution by Application Area
Figure 4.6 Monkeypox Diagnostic Kits: Distribution by Type of Kit
Figure 4.7 Monkeypox Diagnostic Kits: Distribution by Quantity of Sample
Figure 4.8 Monkeypox Diagnostic Kits: Distribution by Turnaround Time
Figure 4.9 Monkeypox Diagnostic Kits: Distribution by Limit of Detection
Figure 4.10 Monkeypox Diagnostic Kits: Distribution by Number of Tests per Kit
Figure 4.11 Monkeypox Diagnostic Kits: Distribution by Shelf Life
Figure 4.12 Monkeypox Diagnostic Kits: Distribution by Storage Temperature
Figure 4.13 Monkeypox Diagnostic Kits Developers: Distribution by Year of Establishment
Figure 4.14 Monkeypox Diagnostic Kits Developers: Distribution by Company Size
Figure 4.15 Monkeypox Diagnostic Kits Developers: Distribution by Location of Headquarters
Figure 4.16 Monkeypox Diagnostic Kits Developers: Distribution by Company Size and Location of Headquarters
Figure 4.17 Monkeypox Diagnostic Kits Developers: Distribution by Type of Developer
Figure 4.18 Leading Developers: Distribution by Number of Diagnostic Kits
Figure 5.1 Product Competitiveness Analysis: Dot-Plot Representation of Monkeypox Diagnostic Kits
Figure 5.2 Product Competitiveness Analysis: Top Monkeypox Diagnostic Kits
Figure 8.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2018-2022
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Focus Area
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.6 Most Active Players: Distribution by Number of Partnerships
Figure 8.7 Partnerships and Collaborations: Local and International Agreements
Figure 8.8 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 Grants Analysis: Distribution by Year of Grant Awarded
Figure 9.2 Grants Analysis: Distribution by Support Period
Figure 9.3 Grants Analysis: Distribution by Amount Awarded
Figure 9.4 Grants Analysis: Distribution by Leading Funding Institute Centre
Figure 9.5 Grants Analysis: Distribution by Type of Grant
Figure 9.6 Grants Analysis: Distribution by Activity Code
Figure 9.7 Grants Analysis: Distribution by Study Section Involved
Figure 9.8 Grants Analysis: Distribution by Purpose of Grant
Figure 9.9 Grants Analysis: Prominent Program Officers
Figure 9.10 Grants Analysis: Popular Recipient Organizations
Figure 9.11 Grants Analysis: Distribution by Popular NIH Departments
Figure 9.12 Grants Analysis: Distribution by Location of Recipient
Figure 10.1 Publication Analysis: Distribution by Year of Publication
Figure 10.2 Publication Analysis: Distribution by Type of Publication
Figure 10.3 Most Popular Journals: Distribution by Number of Publications
Figure 10.4 Most Popular Journals: Distribution by Journal Impact Factor
Figure 10.5 Most Popular Keywords: Distribution by Key Focus Areas
Figure 10.6 Most Active Publishers: Distribution by Number of Publications
Figure 10.7 Most Popular Affiliations: Distribution by Number of Publications
Figure 10.8 Publication Analysis: Distribution by Geography
Figure 11.1 Monkeypox Therapeutics / Vaccines and Diagnostic Kits: Porter’s Five Forces Analysis
Figure 12.1 Global Monkeypox Therapeutics and Vaccines Market, 2023-2035 (USD Billion)
Figure 12.2 Monkeypox Therapeutics and Vaccines Market: Distribution by Type of Product, 2023 and 2035 (USD Billion)
Figure 12.3 Monkeypox Therapeutics Market, 2023-2035 (USD Billion)
Figure 12.4 Monkeypox Vaccines Market, 2023-2035 (USD Billion)
Figure 12.5 Monkeypox Therapeutics and Vaccines Market: Distribution by Drug Developers, 2023 and 2035 (USD Billion)
Figure 12.6 Monkeypox Therapeutics and Vaccines Market for Bavarian Nordic, 2023-2035 (USD Billion)
Figure 12.7 Monkeypox Therapeutics and Vaccines Market for SIGA Technologies, 2023-2035 (USD Billion)
Figure 12.8 Monkeypox Therapeutics and Vaccines Market for Emergent BioSolutions, 2023-2035 (USD Billion)
Figure 12.9 Monkeypox Therapeutics and Vaccines Market for Gilead Sciences, 2023-2035 (USD Billion)
Figure 12.10 Monkeypox Therapeutics and Vaccines Market for KM Biologics, 2023-2035 (USD Billion)
Figure 12.11 Monkeypox Therapeutics and Vaccines Market: Distribution by Drug Candidates, 2023 and 2035 (USD Billion)
Figure 12.12 IMVANEX® / JYNNEOS® / IMVAMUNER® (Bavarian Nordic): Sales Forecast, 2023-2035 (USD Billion)
Figure 12.13 Tecovirimat / ST-246 / TPOXX (SIGA Technologies): Sales Forecast, 2023-2035 (USD Billion)
Figure 12.14 ACAM2000 (Emergent BioSolutions): Sales Forecast, 2023-2035 (USD Billion)
Figure 12.15 VIGIV / CNJ-016 (Emergent BioSolutions): Sales Forecast, 2023-2035 (USD Billion)
Figure 12.16 Brincidofovir / CMX001 / Tembexa (Emergent BioSolutions / SymBio Pharmaceuticals): Sales Forecast, 2023-2035 (USD Billion)
Figure 12.17 Cidofovir / Vistide (Gilead Sciences): Sales Forecast, 2023-2035 (USD Billion)
Figure 12.18 LC16KMB (KM Biologics): Sales Forecast, 2023-2035 (USD Billion)
Figure 12.19 Monkeypox Therapeutics and Vaccines Market: Distribution by Geography, 2023 and 2035 (USD Billion)
Figure 12.20 Monkeypox Therapeutics and Vaccines Market in North America, 2023-2035 (USD Billion)
Figure 12.21 Monkeypox Therapeutics and Vaccines Market in the US, 2023-2035 (USD Billion)
Figure 12.22 Monkeypox Therapeutics and Vaccines Market in Canada, 2023-2035 (USD Billion)
Figure 12.23 Monkeypox Therapeutics and Vaccines Market in Europe, 2023-2035 (USD Billion)
Figure 12.24 Monkeypox Therapeutics and Vaccines Market in the UK, 2023-2035 (USD Billion)
Figure 12.25 Monkeypox Therapeutics and Vaccines Market in France, 2023-2035 (USD Billion)
Figure 12.26 Monkeypox Therapeutics and Vaccines Market in Germany, 2023-2035 (USD Billion)
Figure 12.27 Monkeypox Therapeutics and Vaccines Market in Spain, 2023-2035 (USD Billion)
Figure 12.28 Monkeypox Therapeutics and Vaccines Market in Italy, 2023-2035 (USD Billion)
Figure 12.29 Monkeypox Therapeutics and Vaccines Market in Rest of Europe, 2023-2035 (USD Billion)
Figure 12.30 Monkeypox Therapeutics and Vaccines Market in Asia Pacific, 2023-2035 (USD Billion)
Figure 12.31 Monkeypox Therapeutics and Vaccines Market in Japan, 2023-2035 (USD Billion)
Figure 12.32 Monkeypox Therapeutics and Vaccines Market in Australia, 2023-2035 (USD Billion)
Figure 13.1 Global Monkeypox Diagnostic Kits Market, 2023-2035 (USD Billion)
Figure 13.2 Monkeypox Diagnostic Kits Market: Distribution by Type of Kit, 2023 and 2035 (USD Billion)
Figure 13.3 Monkeypox Diagnostic Kits Market for Polymerase Chain Reaction (PCR) Detection Kits, 2023-2035 (USD Billion)
Figure 13.4 Monkeypox Diagnostic Kits Market for Antigen Detection Kits, 2023-2035 (USD Billion)
Figure 13.5 Monkeypox Diagnostic Kits Market for Antibody Detection Kits, 2023-2035 (USD Billion)
Figure 13.6 Monkeypox Diagnostic Kits Market for Type of End User, 2023 and 2035 (USD Billion)
Figure 13.7 Monkeypox Diagnostic Kits Market for Hospitals and Clinics, 2023-2035 (USD Billion)
Figure 13.8 Monkeypox Diagnostic Kits Market for Diagnostic Laboratories, 2023-2035 (USD Billion)
Figure 13.9 Monkeypox Diagnostic Kits Market for Other End Users, 2023-2035 (USD Billion)
Figure 13.10 Monkeypox Diagnostic Kits Market: Distribution by Geography, 2023 and 2035 (USD Billion)
Figure 13.11 Monkeypox Diagnostic Kits Market in North America, 2023-2035 (USD Billion)
Figure 13.12 Monkeypox Diagnostic Kits Market in the US, 2023-2035 (USD Billion)
Figure 13.13 Monkeypox Diagnostic Kits Market in Canada, 2023-2035 (USD Billion)
Figure 13.14 Monkeypox Diagnostic Kits Market in Europe, 2023-2035 (USD Billion)
Figure 13.15 Monkeypox Diagnostic Kits Market in the UK, 2023-2035 (USD Billion)
Figure 13.16 Monkeypox Diagnostic Kits Market in France, 2023-2035 (USD Billion)
Figure 13.17 Monkeypox Diagnostic Kits Market in Germany, 2023-2035 (USD Billion)
Figure 13.18 Monkeypox Diagnostic Kits Market in Spain, 2023-2035 (USD Billion)
Figure 13.19 Monkeypox Diagnostic Kits Market in Italy, 2023-2035 (USD Billion)
Figure 13.20 Monkeypox Diagnostic Kits Market in Rest of Europe, 2023-2035 (USD Billion)
Figure 13.21 Monkeypox Diagnostic Kits Market in Asia Pacific, 2023-2035 (USD Billion)
Figure 13.22 Monkeypox Diagnostic Kits Market in Japan, 2023-2035 (USD Billion)
Figure 13.23 Monkeypox Diagnostic Kits Market in Australia, 2023-2035 (USD Billion)

List Of Tables

Table 3.1 Monkeypox Market: List of Monkeypox Therapeutics / Vaccines
Table 3.2 Monkeypox Market: List of Monkeypox Therapeutics / Vaccines Developers
Table 4.1 Monkeypox Market: List of Monkeypox Diagnostic Kits
Table 4.2 Monkeypox Market: List of Monkeypox Diagnostic Kits Developers
Table 6.1 Bavarian Nordic: Monkeypox Therapeutics / Vaccines Portfolio
Table 6.2 Bavarian Nordic: Recent Developments and Future Outlook
Table 6.3 Emergent: Monkeypox Therapeutics / Vaccines Portfolio
Table 6.4 Emergent: Recent Developments and Future Outlook
Table 7.1 ACON Laboratories: Monkeypox Diagnostic Kits Portfolio
Table 7.2 altona Diagnostics: Monkeypox Diagnostic Kits Portfolio
Table 7.3 altona Diagnostics: Recent Developments and Future Outlook
Table 7.4 Bioperfectus Technologies: Monkeypox Diagnostic Kits Portfolio
Table 7.5 Bioperfectus Technologies: Recent Developments and Future Outlook
Table 7.6 DNA Software: Monkeypox Diagnostic Kits Portfolio
Table 7.7 Elabscience Biotechnology: Monkeypox Diagnostic Kits Portfolio
Table 7.8 Goldsite Diagnostics: Monkeypox Diagnostic Kits Portfolio
Table 7.9 Lansion Biotechnology: Monkeypox Diagnostic Kits Portfolio
Table 7.10 Testsealabs: Monkeypox Diagnostic Kits Portfolio
Table 7.11 Testsealabs: Recent Developments and Future Outlook
Table 8.1 Monkeypox Therapeutics / Vaccines and Diagnostic Kits: List of Partnerships and Collaborations
Table 9.1 Monkeypox Therapeutics / Vaccines and Diagnostic Kits: List of Grants
Table 10.1 Monkeypox Therapeutics / Vaccines and Diagnostic Kits: List of Publications
Table 15.1 Monkeypox Therapeutics / Vaccines: Distribution by Phase of Development
Table 15.2 Monkeypox Therapeutics / Vaccines: Distribution by Type of Product
Table 15.3 Monkeypox Therapeutics / Vaccines: Distribution by Phase of Development and Type of Product
Table 15.4 Monkeypox Therapeutics / Vaccines: Distribution by Type of Molecule
Table 15.5 Monkeypox Therapeutics / Vaccines: Distribution by Type of Dosage Form
Table 15.6 Monkeypox Therapeutics / Vaccines: Distribution by Route of Administration
Table 15.7 Monkeypox Therapeutics / Vaccines Developers: Distribution by Year of Establishment
Table 15.8 Monkeypox Therapeutics / Vaccines Developers: Distribution by Type of Player
Table 15.9 Monkeypox Therapeutics / Vaccines Developers: Distribution by Geography (Region-wise)
Table 15.10 Monkeypox Therapeutics / Vaccines Developers: Distribution by Company Size and Geography (Region-wise)
Table 15.11 Leading Developers: Distribution by Number of Therapeutics / Vaccines
Table 15.12 Monkeypox Diagnostic Kits: Distribution by Type of Sample
Table 15.13 Monkeypox Diagnostic Kits: Distribution by Type of Kit Component
Table 15.14 Monkeypox Diagnostic Kits: Distribution by Clade of Virus Detected
Table 15.15 Monkeypox Diagnostic Kits: Distribution by Detection Method
Table 15.16 Monkeypox Diagnostic Kits: Distribution by Application Area
Table 15.17 Monkeypox Diagnostic Kits: Distribution by Type of Kit
Table 15.18 Monkeypox Diagnostic Kits: Distribution by Quantity of Sample
Table 15.19 Monkeypox Diagnostic Kits: Distribution by Turnaround Time
Table 15.20 Monkeypox Diagnostic Kits: Distribution by Limit of Detection
Table 15.21 Monkeypox Diagnostic Kits: Distribution by Number of Tests per Kit
Table 15.22 Monkeypox Diagnostic Kits: Distribution by Shelf Life
Table 15.23 Monkeypox Diagnostic Kits: Distribution by Storage Temperature
Table 15.24 Monkeypox Diagnostic Kits Developers: Distribution by Year of Establishment
Table 15.25 Monkeypox Diagnostic Kits Developers: Distribution by Company Size
Table 15.26 Monkeypox Diagnostic Kits Developers: Distribution by Location of Headquarters
Table 15.27 Monkeypox Diagnostic Kits Developers: Distribution by Company Size and Location of Headquarters
Table 15.28 Monkeypox Diagnostic Kits Developers: Distribution by Type of Developer
Table 15.29 Leading Developers: Distribution by Number of Diagnostic Kits
Table 15.30 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2018-2022
Table 15.31 Partnerships and Collaborations: Distribution by Type of Partnership
Table 15.32 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 15.33 Partnerships and Collaborations: Distribution by Focus Area
Table 15.34 Partnerships and Collaborations: Distribution by Type of Partner
Table 15.35 Most Active Players: Distribution by Number of Partnerships
Table 15.36 Partnerships and Collaborations: Local and International Agreements
Table 15.37 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 15.38 Grants Analysis: Distribution by Year of Grant Awarded
Table 15.39 Grants Analysis: Distribution by Support Period
Table 15.40 Grants Analysis: Distribution by Amount Awarded
Table 15.41 Grants Analysis: Distribution by Leading Funding Institute Centre
Table 15.42 Grants Analysis: Distribution by Type of Grant
Table 15.43 Grants Analysis: Distribution by Activity Code
Table 15.44 Grants Analysis: Distribution by Study Section Involved
Table 15.45 Grants Analysis: Distribution by Purpose of Grant
Table 15.46 Grants Analysis: Prominent Program Officers
Table 15.47 Grants Analysis: Popular Recipient Organizations
Table 15.48 Grants Analysis: Distribution by Popular NIH Departments
Table 15.49 Grants Analysis: Distribution by Location of Recipient
Table 15.50 Publication Analysis: Distribution by Year of Publication
Table 15.51 Publication Analysis: Distribution by Type of Publication
Table 15.52 Most Popular Journals: Distribution by Number of Publications
Table 15.53 Most Popular Journals: Distribution by Journal Impact Factor
Table 15.54 Most Popular Keywords: Distribution by Key Focus Areas
Table 15.55 Most Active Publishers: Distribution by Number of Publications
Table 15.56 Most Popular Affiliations: Distribution by Number of Publications
Table 15.57 Publication Analysis: Distribution by Geography
Table 15.58 Global Monkeypox Therapeutics and Vaccines Market, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.59 Monkeypox Therapeutics and Vaccines Market: Distribution by Type of Product, 2023 and 2035 (USD Billion)
Table 15.60 Monkeypox Therapeutics and Vaccines Market for Therapeutics, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.61 Monkeypox Therapeutics and Vaccines Market for Vaccines, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.62 Monkeypox Therapeutics and Vaccines Market: Distribution by Drug Developers, 2023 and 2035 (USD Billion)
Table 15.63 Monkeypox Therapeutics and Vaccines Market for Bavarian Nordic, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.64 Monkeypox Therapeutics and Vaccines Market for SIGA Technologies, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.65 Monkeypox Therapeutics and Vaccines Market for Emergent BioSolutions, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.66 Monkeypox Therapeutics and Vaccines Market for Gilead Sciences, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.67 Monkeypox Therapeutics and Vaccines Market for KM Biologics, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.68 Monkeypox Therapeutics and Vaccines Market: Distribution by Drug Candidates, 2023 and 2035 (USD Billion)
Table 15.69 IMVANEX® / JYNNEOS® / IMVAMUNER® (Bavarian Nordic): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.70 Tecovirimat / ST-246 / TPOXX (SIGA Technologies): Sales Forecast, 2023-2035 Conservative, Base and Optimistic Scenarios, (USD Billion)
Table 15.71 ACAM2000 (Emergent BioSolutions): Sales Forecast, 2023-2035 Conservative, Base and Optimistic Scenarios, (USD Billion)
Table 15.72 VIGIV / CNJ-016 (Emergent BioSolutions): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.73 Brincidofovir / CMX001 / Tembexa (Emergent BioSolutions / SymBio Pharmaceuticals): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.74 Cidofovir / Vistide (Gilead Sciences): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.75 LC16KMB (KM Biologics): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.76 Monkeypox Therapeutics and Vaccines Market: Distribution by Geography, 2023 and 2035 (USD Billion)
Table 15.77 Monkeypox Therapeutics and Vaccines Market in North America, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.78 Monkeypox Therapeutics and Vaccines Market in the US, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.79 Monkeypox Therapeutics and Vaccines Market in Canada, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.80 Monkeypox Therapeutics and Vaccines Market in Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.81 Monkeypox Therapeutics and Vaccines Market in the UK, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.82 Monkeypox Therapeutics and Vaccines Market in France, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.83 Monkeypox Therapeutics and Vaccines Market in Germany, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.84 Monkeypox Therapeutics and Vaccines Market in Spain, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.85 Monkeypox Therapeutics and Vaccines Market in Italy, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.86 Monkeypox Therapeutics and Vaccines Market in Rest of Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.87 Monkeypox Therapeutics and Vaccines Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.88 Monkeypox Therapeutics and Vaccines Market in Japan, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.89 Monkeypox Therapeutics and Vaccines Market in Australia, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.90 Global Monkeypox Diagnostic Kits Market, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.91 Monkeypox Diagnostic Kits Market: Distribution by Type of Kit, 2023 and 2035 (USD Billion)
Table 15.92 Monkeypox Diagnostic Kits Market for Polymerase Chain Reaction (PCR) Detection Kits, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.93 Monkeypox Diagnostic Kits Market for Antigen Detection Kits, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.94 Monkeypox Diagnostic Kits Market for Antibody Detection Kits, 2023 and 2035 (USD Billion)
Table 15.95 Monkeypox Diagnostic Kits Market for Type of End User, 2023-2035 (USD Billion)
Table 15.96 Monkeypox Diagnostic Kits Market for Hospitals and Clinics, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.97 Monkeypox Diagnostic Kits Market for Diagnostic Laboratories, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.98 Monkeypox Diagnostic Kits Market for Other Users, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.99 Monkeypox Diagnostic Kits Market: Distribution by Geography, Conservative, Base and Optimistic Scenarios, 2023 and 2035 (USD Billion)
Table 15.100 Monkeypox Diagnostic Kits Market in North America, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.101 Monkeypox Diagnostic Kits Market in the US, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.102 Monkeypox Diagnostic Kits Market in Canada, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.103 Monkeypox Diagnostic Kits Market in Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.104 Monkeypox Diagnostic Kits Market in the UK, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.105 Monkeypox Diagnostic Kits Market in France, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.106 Monkeypox Diagnostic Kits Market in Germany, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.107 Monkeypox Diagnostic Kits Market in Spain, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.108 Monkeypox Diagnostic Kits Market in Italy, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.109 Monkeypox Diagnostic Kits Market in Rest of Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.110 Monkeypox Diagnostic Kits Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.111 Monkeypox Diagnostic Kits Market in Japan, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 15.112 Monkeypox Diagnostic Kits Market in Australia, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. 3D Medicines
  2. Abbott
  3. Abebio
  4. ACON Laboratories
  5. Advanced Molecular Diagnostics
  6. AEHEALTH
  7. altona Diagnostics
  8. Anatolia Geneworks
  9. Anbio (Xiamen) Biotechnology
  10. Applied DNA Sciences
  11. Arizona State University
  12. Atlas Link Biotech
  13. Aurora
  14. Battelle
  15. Bavarian Nordic
  16. Becton Dickinson
  17. BEI Resources
  18. Beijing Applied Biological Technologies
  19. Better2Know
  20. BGI Genomics
  21. BIOBASE
  22. BioFactura
  23. BioGX
  24. BIOHIT Healthcare (Hefei)
  25. BioinGentech
  26. Bioneer
  27. Bioperfectus
  28. BioTeke
  29. Blue Water Vaccines
  30. Boditech Med
  31. Canadian Department of National Defence
  32. CAPRISA
  33. Center for Disease Control and Prevention
  34. Cepheid
  35. CerTest Biotec
  36. Changzhou Biowin Pharmaceutical
  37. Chimerix
  38. Chinese Academy of Medical Sciences
  39. Cincinnati Children’s Hospital Medical Center
  40. CorDx
  41. Cosmos Holdings
  42. Creative Biogene
  43. CureVac
  44. Daan Gene
  45. Directorate-General of Health
  46. Division of Basic Sciences - NCI
  47. DNA Software
  48. Elabscience
  49. Elisabeth Pharmacon
  50. ELITechGroup
  51. Emergent BioSolutions
  52. EpiVax
  53. Era Biology
  54. European Centre for Disease Prevention and Control
  55. European Health Emergency Preparedness and Response Authority
  56. Fapon Biotech
  57. FireGene
  58. Fox Chase Cancer Center
  59. Fox Chase Chemical Diversity Center
  60. Fundación Universitaria Autónoma de las Américas
  61. Genekam Biotechnology
  62. Genematrix
  63. Genes Lab
  64. Genes2Me
  65. GenScript
  66. GeoVax
  67. Getein Biotech
  68. Gilead Sciences
  69. Goldsite Diagnostics
  70. Grand River Aseptic Manufacturing
  71. Hangzhou Bigfish Bio-tech
  72. Hangzhou Bioer Technology
  73. Hangzhou Testsea Biotechnology
  74. Healgen Scientific
  75. Heas Biotech
  76. Holborn Wells
  77. Huachenyang (Shenzhen) Technology
  78. Humasis
  79. Hybribio
  80. ICMR
  81. iGene Laboratory
  82. ImmunoDiagnostics
  83. Imperial College
  84. Inovia Technology
  85. Inovio Pharmaceuticals
  86. Integrity Laboratories
  87. Israel Institute for Biological Research
  88. Jiangsu Kangpu Biomedical Technology
  89. Jiangsu Medomics Medical Technology
  90. Jiangsu Mole Bioscience
  91. Jinan Babio Biotechnology
  92. JOYSBIO (Tianjin) Biotechnology
  93. Kenya Medical Research Institute
  94. KH Medical
  95. Kinshasa School of Public Health
  96. KM Biologics (a Meiji Holdings Company)
  97. Lansion Biotechnology
  98. Leidos Biomedical Research
  99. LifePharm
  100. Liferiver Biotech
  101. Lifotronic
  102. Liverpool University Hospitals NHS Foundation Trust
  103. Lovelace Biomedical
  104. Macro & Micro-Test
  105. MacroGenics
  106. Massachusetts Institute of Technology
  107. Medical University of South Carolina
  108. MegaRobo
  109. Ministry of Health
  110. Moderna
  111. MyBioSource
  112. Mylab Discovery Solutions
  113. Najit Technologies
  114. Nanjing Norman Biological Technology
  115. Nanjing Synthgene Medical Technology
  116. NanoViricides
  117. National Institute of Allergy and Infectious Diseases
  118. National Institute of Infectious Diseases
  119. National Research Center for Epidemiology and Microbiology
  120. NeoDx
  121. Oregon Health & Science University
  122. Oxford University
  123. Pan American Health Organization
  124. Pasteur Institute
  125. PCL
  126. PerkinElmer
  127. Precigenome
  128. Primer Design
  129. Public Health Agency of Canada
  130. Public Health England
  131. Ramathibodi Hospital’s Centre for Genomics
  132. RayBiotech
  133. REALY
  134. Roche
  135. Runmei Gene
  136. Russian State Research Centre of Virology / Biotechnology VECTOR
  137. Saint Louis University
  138. Sansure Biotech
  139. ScienCell
  140. SD Biosensor
  141. Seasun Bio
  142. SG Diagnostics
  143. Shanghai Biogerm Medical Technology
  144. Shenzhen Lyttop Healthcare
  145. Shenzhen Ultra-Diagnostics Biotech
  146. Shenzhen Watmind Medical
  147. Shenzhen Zijian Biotechnology
  148. SIGA Technologies
  149. Singclean Medical
  150. Singuway Biotech
  151. State Research Center of Virology and Biotechnology Vector
  152. Sugentech
  153. Syiah Kuala University
  154. SymBio Pharmaceuticals
  155. Symphogen
  156. TargetingOne
  157. The Near East University 
  158. The University of Jordan
  159. The University of Massachusetts Chan Medical School
  160. The University of Texas Health Science Center
  161. TianLong
  162. Tonix Pharmaceuticals
  163. Transasia Bio-Medicals
  164. TransGen Biotech
  165. Trivitron Healthcare
  166. Ugenecell
  167. UK Health Security Agency
  168. Ultrassay Biotech
  169. University College London
  170. University Medical Center Hamburg-Eppendorf
  171. University of California
  172. University of Kinshasa
  173. University of Liverpool
  174. University of Oklahoma Health Sciences Center
  175. University of Pennsylvania
  176. University of Reading
  177. University of Rochester
  178. University of Würzburg
  179. US Army Medical Research Institute of Infectious Diseases
  180. US Biomedical Advanced Research and Development Authority
  181. US Department of Defense
  182. Vanderbilt University Medical Center
  183. Vela Diagnostics
  184. Virax Biolabs
  185. Vircell
  186. Vitrosens
  187. VivaChek Biotech
  188. Washington University
  189. Wells Bio
  190. Wizbiosolutions
  191. Wondfo
  192. Wuhan Fine Biotech
  193. Wuhan JH Bio-Tech
  194. Xiamen Biotime Biotechnology
  195. Xiamen Jiqing Biomedical Technology
  196. Xiamen Zeesan Biotech
  197. Yixin Bio-Tech
  198. YouSeq

Source 1: https://www.citizen.org/article/letter-to-bavarian-nordic-urging-equitable-access/
Source 2: https://jamanetwork.com/journals/jama/fullarticle/2794922#:~:text=On%20July%2023%2C%202022,9%20against%20recommending%20a%20PHEIC

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com